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Abstract
Background: While the N-terminal pro-brain-type natriuretic peptide (NT-proBNP) at rest is known to be associated with
prognosis in pulmonary arterial hypertension (PAH), it is unclear if the NT-proBNP response to exercise (ΔNT-proBNP) can
contribute to a better assessment of disease severity.
Methods: We investigated the association of NT-proBNP values at rest and during peak exercise with hemodynamics and
cardiopulmonary exercise testing parameters in 63 therapy-naive PAH patients.
Results: The median NT-proBNP increases from 1414 at rest to 1500 pg/ml at peak exercise. The ΔNT-proBNP is baseline-
dependent in PAH. Both, NT-proBNP at rest and NT-proBNP at peak exercise, are significantly correlated with
hemodynamics and functional capacity. However, neither NT-proBNP at peak exercise nor ΔNT-proBNP correlated better
with surrogate markers of disease severity than NT-proBNP at rest.
Conclusion: The ΔNT-proBNP does not contribute to a better assessment of disease severity in PAH.
Keywords: N-terminal pro-brain-type natriuretic peptide (NT-proBNP), Response to exercise, Pulmonary arterial
hypertension (PAH), Exercise capacity, Hemodynamics
Background
Although medical therapy is available, pulmonary arter-
ial hypertension (PAH) is a progressive disease leading
to a reduction in exercise capacity and, more severely, to
a decreased life expectancy [1]. In order to evaluate the
progress of the disease, a number of prognostic parame-
ters were established, including hemodynamics and
cardiopulmonary exercise testing (CPET) [2].
As right ventricular (RV) dysfunction is one of the
most important factors contributing to functional
impairment and mortality [3], the plasma concentration
of N-terminal pro-brain-type natriuretic peptide (NT-
proBNP) is supposed to be another prognostic marker.
NT-proBNP is formed through enzymatic cleavage of
proBNP into the two split products NT-proBNP and the
biologically active BNP. ProBNP is released from the
myocytes mainly in response to cardiac wall stress. BNP
and NT-proBNP are produced on an equimolar basis,
however, as NT-proBNP has a longer half-life and higher
sample stability, NT-proBNP is the more advantageous
diagnostic marker [4].
While the NT-proBNP level at rest is associated with
prognosis in PAH [5], it is yet to evaluate if the NT-
proBNP response to exercise (ΔNT-proBNP) can contrib-
ute to a better assessment of disease severity. Therefore,
we investigated the association of NT-proBNP values at
rest and during peak exercise with hemodynamics and
functional capacity, important surrogate parameters of
disease severity in PAH.
* Correspondence: thomas.berghaus@klinikum-augsburg.de
Department of Cardiology, Respiratory Medicine and Intensive Care, Klinikum
Augsburg, Ludwig-Maximilians-University Munich, Stenglinstrasse 2, 86156
Augsburg, Germany
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kutsch et al. Respiratory Research  (2018) 19:8 
DOI 10.1186/s12931-017-0712-9
Methods
Study design
From August 2009 until March 2016, 63 therapy-naive
PAH patients were recruited. Patients with a serum
creatinine of >1.3 mg/dl, a glomerular filtration rate <
50 ml/min/1.73 m2, congenital heart diseases or signs of
acute right heart decompensation were excluded from
the study. All study participants underwent six-minute
walking testing (6MWT), CPET, lung function testing
and right heart catheterisation. Evaluation of exercise
capacity and hemodynamics were used as surrogate
parameters of disease severity in our trial. All examina-
tions were performed within three consecutive work-
days. The study was approved by the local Ethics
Committee (project number 201604). Data analysis was
performed retrospectively.
Right heart catheterisation
In order to confirm precapillary pulmonary hyperten-
sion (PH), all patients underwent right heart
catheterisation. A thermodilution catheter (7.5 F
quadruple-lumen, balloon-tipped, flow-directed, „S
“Tip Swan-Ganz Catheter, Edwards Lifesciences,
Irvine, USA) was used. The catheter was inserted via
the right or left femoral vein and hemodynamic mea-
surements were taken in supine position. Those
included heart rate, PCWP, PAP, cardiac output (CO),
cardiac index (CI), pulmonary vascular resistance
(PVR), right atrial pressure (RAP) and mixed venous
oxygen saturation (SVO2). The CO was determined
via thermodilution measurements. A computer system
(Com-2, Cardiac Output Computer, Edwards Life-
sciences, Irvine, USA) was used for calculations.
10 ml sterile, ice-cold isotonic (0.9%) saline was
injected through the right atrial lumen of the catheter
and measured by a thermistor placed directly behind
the right atrial inlet of the catheter. The distal
thermistor then recorded the drop in temperature. A
minimum of three measurements was performed and
the mean value was calculated provided that the
variation was less than 10%. The CI was calculated
forming the quotient of CO and body surface area.
PVR was computed using the standard formula [PVR
= (mean PAP-PCWP)/CO].
Lung function test
In order to examine the pulmonary function of the pa-
tients, spirometry and body plethysmography were
performed. The diffusing capacity was tested via the
single-breath method (Master Screen Body and MS-PFT,
Jaeger, Cardinal Health, USA). Blood gas analysis was
measured using arterialised capillary blood taken from
the earlobe. No supplemental oxygen was given. Lung
function parameters determined were total lung capacity
(TLC), forced vital capacity (FVC), forced expiratory vol-
ume in one second (FEV1) and diffusing capacity for
carbon monoxide (DLCO).
Cardiopulmonary exercise testing (CPET)
An electromagnetically braked cycle ergometer (ViaSpring
150p, Ergoline, Germany) was used following a standar-
dised protocol [6].
After a warming phase, the work rate elevated by 5 to
15 watts/min until the maximum exercise capacity was
reached. This was defined as the moment when patients
could no longer tolerate the symptoms. Maximum work
rate was documented. While the pulse was continuously
recorded, the blood pressure was measured non-
invasively every two minutes. With an adult facemask
(Vmax spectra 229 D, Sensor Medics, USA) minute
ventilation (Ve) and CO2 output were recorded. The
maximum O2 uptake (peak VO2) was determined taking
the average O2 uptake during the last 15 s of CPET.
Blood gas analysis was done at rest and at peak exercise.
We calculated O2 pulse, alveolar-arterial O2 difference
(AaDO2) and functional dead space ventilation (Vd/Vt).
The anaerobic threshold (AT) was defined as the O2
uptake patients reached in the moment the ventilatory
equivalent for O2 (VE/VO2) still increased and the
ventilatory equivalent for CO2 (Ve/CO2) decreased or
stagnated. The VE/VCO2 slope was taken from the be-
ginning of exercise until the respiratory compensation
point, when acidaemia stimulated the ventilation and the
end-tidal CO2 started to decrease.
NT-proBNP
NT-proBNP values were measured twice using capillary
blood taken from the earlobe immediately before
performing the CPET and after reaching peak exercise
capacity. The one-step sandwich chemiluminescent
immunoassay (Dimension Vista System, Siemens
Healthcare Diagnostics Inc., Newark, USA) was used. In
order to avoid an underestimation or overestimation of
absolute values, measured NT-proBNP levels were
divided by the age-adjusted normal upper range to
calculate the normalised NT-proBNP ratio. Conse-
quently, elevated levels result in a normalized NT-
proBNP ratio > 1.
Six-minute walking test (6MWT)
Patients were encouraged to walk a 30 m long corridor
as many times as possible in six minutes. The number of
breaks was recorded. The achieved walking distance was
set in ratio to age and gender. Immediately after the test,
patients were asked to rate their perceived level of ex-
haustion on the Borg scale ranging from 0 (no dyspnea)
to 10 (extreme dyspnea) [7].
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Statistics
Statistical analysis was performed with IBM SPSS Statis-
tics 23. Data was checked for normal distribution using
graphic methods as well as the Shapiro-Wilk test. Mean
and standard error of the mean (SEM) were calculated
for data with normal distribution, median with range for
those without.
Nominal variables are shown as numbers with
percentage of total. We used the Spearman’s rank correl-
ation coefficient to examine the relation between
NT-proBNP values and other parameters. Correlation is
strongest if the coefficient is close to −1 or 1. No correl-
ation is apparent if the coefficient is 0. Significance was
tested two-tailed and assumed statistically significant if
p-values were <0.05.
Results
Patients’ characteristics
Sixty-three patients (32 females and 31 males, mean age
66.1 ± 1.7 years) could be included in our study. All
study participants suffered from PAH with a mean PAP
of 39.0 ± 1.5 mmHg. The median NT-proBNP value at
rest was 1414 (38–13,538) pg/ml. In Table 1, further
clinical characteristics of the study cohort are
summarised.
NT-proBNP levels in different risk groups
Based on the NT-proBNP level at rest, the study
population was divided into three groups. The NT-
proBNP <300 pg/ml group showed a median re-
sponse to exercise of 6 pg/ml, the NT-proBNP 300–
1400 pg/ml and the NT-proBNP >1400 pg/ml groups
showed higher absolute ΔNT-proBNP, 60 pg/ml and
200 pg/ml, respectively. Additional information is
shown in Table 2.
Correlations of NT-proBNP and ΔNT-proBNP with
hemodynamics and exercise capacity
Strong and highly significant correlations were found be-
tween NT-proBNP at rest and at peak exercise with
parameters of 6MWT, hemodynamics and CPET. With
the majority of parameters, NT-proBNP at rest showed
marginally better correlations than NT-proBNP at
exercise. Exceptions are CO and PVR. In contrast, lung
function parameters showed only weak correlations with
NT-proBNP levels at rest or at peak exercise. The ΔNT-
proBNP only correlated significantly with the 6MWT
distance, AaDO2 and the Ve/VCO2 slope (see Table 3).
Correlations of NT-proBNP and ΔNT-proBNP with the
6MWT distance, mean PAP and the VO2/kg are shown
as plots in Additional file 1. They show that the correla-
tions of ΔNT-proBNP values with hemodynamics and
functional capacity are worse compared to NT-proBNP
levels at rest or at peak exercise.
Discussion
Our study was conducted in order to evaluate if the NT-
proBNP response to exercise can contribute to a better
assessment of disease severity in PAH.
First, we were able to demonstrate that NT-proBNP
levels increase in response to exercise in PAH patients.
Similar findings have already been made in studies
Table 1 Patients characteristics (n = 63)
Clinical profile
Female/male [n (%)] 32 (50.2) / 31 (49.8)
Age (years) 66.1 ± 1.7
BMI (kg/m2) 26.0 (18.0–43.0)
NT-proBNP
NT-proBNP at rest (pg/ml) 1414 (38–13,538)
NT-proBNP at exercise (pg/ml) 1500 (42–14,365)
NT-proBNP ratio 6.95 (0.09–60.60)
ΔNT-proBNP (pg/ml) 77 (0–1160)
6-min walking test
Distance (m) 300 (100–570)
% of norm (%) 63.0 ± 3.2
Breaks (n) 0 (0–4)
Borg scale points (1–10) 4 (0–10)
Right heart catheterisation
Mean PAP (mmHg) 39.0 ± 1.5
Cardiac output (l/min) 4.10 (2.30–8.90)
Cardiac index (l/min/m2) 2.35 ± 0.10
PVR (Wood Units) 7.45 (3.04–14.20)
Mean RAP (mmHg) 6.00 (1.00–20.00)
SvO2 (%) 61.1 ± 1.04
Lung function
DLCO (%) 52.6 ± 3.30
PaO2 at rest (mmHg) 58.0 ± 1.70
PaO2 at peak exercise (mmHg) 58.0 ± 2.27
Cardiopulmonary exercise testing
Work capacity (watts) 45.0 (25–122)
VO2 (ml/min) 941 ± 41.5
VO2 (ml/min/kg) 12.7 ± 0.5
AT (ml/min/kg) 9.43 ± 0.37
O2 pulse at peak exercise (ml/min/beat) 8.46 ± 0.34
Ve (L/min) 50.8 ± 2.23
Ve/VO2 39.0 (25.0–77.0)
Ve/VCO2 44.0 (28.0–87.0)
AaDO2 (mmHg) 48.1 ± 2.2
Vd/Vt (%) 36.7 ± 1.7
Ve/VCO2 Slope 39.5 (14.3–107)
When not stated otherwise, data are presented as mean± SEM or as
median (range)
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investigating left heart disease [8–10], and in one very
small cohort, consisting of only 20 patients with
precapillary PH [11]. However, there is another trial ad-
dressing the ΔNT-proBNP in PAH patients which
showed no such effect [12]. While the design of the
study was comparable to ours, patients investigated by
Völkers and colleagues [12] were already on specific
PAH medication and showed much lower NT-proBNP
levels at rest. In left heart disease, low NT-proBNP levels
at rest are supposed to be strong predictors for low
exercise-induced changes [9, 10]. Thus, we divided our
patients into three groups, based on the NT-proBNP
levels at rest. The groups were formed according to the
current NT-proBNP-based risk stratification model for
Table 2 NT-proBNP response to exercise according to different NT-proBNP levels at rest
NT-proBNP at rest <300 pg/ml 300–1400 pg/ml >1400 pg/ml
Number (n) 10 21 32
NT-proBNP at rest 84 (38–246) 821 (426–1300) 3145 (1414–13,538)
NT-proBNP at exercise 95 (42–281) 844 (450–1500) 3251 (1500–14,365)
ΔNT-proBNP absolute 10 (0–49) 60 (0–400) 200 (0–1160)
When not stated otherwise, data are presented as median (minimum - maximum) in pg/ml
Table 3 Correlation of NT-proBNP and Δ NT-proBNP with hemodynamics and exercise capacity at rest and at peak exercise
NT-proBNP at rest NT-proBNP at peak exercise Δ NT-proBNP
level ratio level level
n r p r p r p r p
6MWT
Distance (m) 61 −0.507 <0.001 −0.328 0.010 −0.490 <0.001 −0.256 0.047
% of norm 61 −0.546 <0.001 −0.481 <0.001 −0.534 <0.001 −0.310 0.015
Breaks (n) 63 0.556 <0.001 0.484 <0.001 0.541 <0.001 0.183 0.152
Borg scale 63 0.271 0.032 0.245 0.053 0.260 0.039 0.033 0.800
Hemodynamics
Mean PAP (mmHg) 63 0.341 0.006 0.521 0.001 0.335 0.007 0.110 0.391
Cardiac output (l/min) 62 −0.322 0.011 −0.228 0.074 −0.325 0.01 −0.215 0.093
Cardiac index (l/min/m2) 36 −0.384 0.021 −0.360 0.031 −0.384 0.021 −0.248 0.145
PVR (wood units) 56 0.359 0.007 0.476 <0.001 0.361 0.006 0.226 0.094
Mean RAP (mmHg) 57 0.231 0.083 0.281 0.034 0.220 0.100 0.149 0.269
SVO2 (%) 61 −0.530 <0.001 −0.443 <0.001 −0.515 <0.001 −0.208 0.107
Lung function
DLCO (%) 44 −0.332 0.028 −0.270 0.077 −0.314 0.038 −0.182 0.238
PaO2 at rest (mmHg) 63 −0.312 0.013 −0.233 0.066 −0.295 0.019 −0.029 0.824
PaO2 at exercise (mmHg) 63 −0.221 0.081 −0.174 0.171 −0.202 0.113 −0.068 0.599
CPET
Work (watts) 63 −0.438 <0.001 −0.280 0.026 −0.410 0.001 −0.074 0.567
VO2 (ml/min) 63 −0.492 <0.001 −0.335 0.007 −0.473 <0.001 −0.136 0.289
VO2/kg 63 −0.514 <0.001 −0.436 <0.001 −0.490 <0.001 −0.193 0.130
AT (ml/min/kg) 48 −0.307 0.034 −0.335 0.062 −0.272 0.020 −0.165 0.263
O2 pulse (ml/min/beat) 62 −0.362 0.004 −0.290 0.022 −0.356 0.004 −0.089 0.491
Ve (l/min) 63 −0.024 0.853 0.092 0.472 −0.007 0.955 0.183 0.151
Ve/VO2 49 0.479 <0.001 0.398 0.005 0.463 0.001 0.241 0.096
Ve/VCO2 49 0.465 0.001 0.361 0.011 0.446 0.001 0.219 0.131
AaDO2 (mmHg) 63 0.452 <0.001 0.395 0.001 0.442 <0.001 0.320 0.011
Vd/Vt (%) 62 0.349 0.005 0.296 0.019 0.335 0.008 0.130 0.314
Ve/VCO2 slope 62 0.471 <0.001 0.435 <0.001 0.466 <0.001 0.330 0.009
Kutsch et al. Respiratory Research  (2018) 19:8 Page 4 of 6
clinical worsening or short-term mortality in PAH [1].
While only a very mild ΔNT-proBNP could be demon-
strated for the group with a low NT-proBNP at rest, the
NT-proBNP response to exercise increased with rising
baseline levels. For example, comparable exercise-
induced NT-proBNP changes could be demonstrated in
patients from our low-level group and study participants
in the trial by Völkers et al. [12]. We therefore conclude
that, like in left heart disease [9, 10], NT-proBNP at rest
seems to be a predictor for the exercise-induced ΔNT-
proBNP.
PH patients with a strong NT-proBNP response to ex-
ercise are supposed to be limited primarily by RV dys-
function due to an impaired lung perfusion. Indeed, we
found in PAH that both NT-proBNP at rest and NT-
proBNP at peak exercise are significantly correlated with
hemodynamics. These findings are in accordance with
an earlier study, where NT-proBNP at rest has been
found to be an independent predictor for hemodynamic
parameters in cardiopulmonary diseases [3]. We also
found a strong correlation of NT-proBNP and NT-
proBNP at peak exercise with CPET parameters, as exer-
cise capacity is believed to be primarily limited by
cardiopulmonary function [13]. No such correlations
were found between NT-proBNP and its response to
exercise with parameters of lung function, as NT-
proBNP gives only indirect information about ventila-
tion. Because the NT-proBNP response to exercise is
baseline-dependent in PAH, neither NT-proBNP at peak
exercise nor ΔNT-proBNP correlated better with
prognostic parameters than NT-proBNP at rest.
Unarguably, our study has limitations. First, due to
the advanced age of the study cohort, comorbidity
might have biased the results. To reduce this effect,
we excluded patients with severe kidney dysfunction,
congenital heart disease or patients with acute right
heart failure. Second, the NT-proBNP response to
exercise might be different in PAH subgroups. Finally,
the prognostic relevance of our observations remains
unclear, as our study does not include long-term fol-
low up results.
Conclusions
Despite these limitations, we conclude the following:
NT-proBNP increases in response to exercise in PAH.
The ΔNT-proBNP seems to be baseline-dependent.
Both NT-proBNP at rest and NT-proBNP at peak ex-
ercise are significantly correlated with hemodynamics
and functional capacity. Neither NT-proBNP at peak
exercise nor ΔNT-proBNP correlated better with
surrogate markers of disease severity than NT-
proBNP at rest. Thus, the NT-proBNP response to
exercise does not contribute to a better assessment of
disease severity in PAH.
Additional file
Additional file 1: Correlation plots of NT-proBNP at rest and at peak
exercise and the ΔNT-proBNP with the 6MWT distance, mean PAP and
the VO2/kg. (ZIP 540 kb)
Abbreviations
6MWT: Six-minute walking testing; AaDO2: Alveolar-arterial oxygen difference
at peak exercise; AT: Anaerobic threshold; BMI: Body mass index; CI: Cardiac
index; CO: Cardiac output; CPET: Cardiopulmonary exercise testing; DLCO: Lung
diffusing capacity for carbon monoxide; FEV1: Forced expiratory volume in one
second; FVC: Forced vital capacity; NT-proBNP ratio: NT-proBNP level at rest
divided by the age-adjusted normal upper range; NT-proBNP: N-terminal
pro-brain-type natriuretic peptide; PAH: Pulmonary arterial hypertension;
PaO2: Arterial oxygen pressure; PAP: Pulmonary arterial pressure; PCWP: Pulmonary
capillary wedge pressure; PH: Pulmonary hypertension; PVR: Pulmonary vascular
resistance; RAP: Right atrial pressure; RV: Right ventricular; SEM: Standard error of
mean; SvO2: Mixed venous oxygen saturation; TLC: Total lung capacity; Vd/
Vt: Functional dead space ventilation at peak exercise; Ve: Peak minute ventilation;
Ve/VCO2 slope: Slope of minute ventilation to carbon dioxide output; Ve/
VCO2: Carbon dioxide equivalent at anaerobic threshold; Ve/VO2: Oxygen
equivalent at anaerobic threshold; VO2: Peak oxygen uptake; ΔNT-
proBNP: NT-proBNP level at exercise minus NT-proBNP level at rest
Acknowledgements
All authors acknowledge the excellent assistance of Yvonne Eglinger in proof
reading the manuscript.
Funding
The study was conducted without funding.
Availability of data and materials
The datasets used and analysed during the current study are available from
the corresponding author on reasonable request.
Authors’ contributions
WS, MS and TMB conceived and designed the study. CF and MS acquired the
study data. JK performed the statistical analysis. JK and TMB drafted the article.
All authors participated in interpreting the data and revised the manuscript for
important intellectual content. All authors approved the final version of the
manuscript.
Ethics approval and consent to participate
The study was conducted in accordance with current ethical standards and
was approved by the ethics committee at the Klinikum Augsburg (reference
number 201604).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 31 May 2017 Accepted: 28 December 2017
References
1. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G,
Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez
MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T,
Pierard LA, Trindade PT, Zompatori M, Hoeper M, Aboyans V, Vaz Carneiro
A, Achenbach S, Agewall S, Allanore Y, Asteggiano R, Paolo Badano L, Albert
Barberà J, Bouvaist H, Bueno H, Byrne RA, Carerj S, Castro G, Erol Ç, Falk V,
Funck-Brentano C, Gorenflo M, Granton J, Iung B, Kiely DG, Kirchhof P,
Kjellstrom B, Landmesser U, Lekakis J, Lionis C, Lip GY, Orfanos SE, Park MH,
Kutsch et al. Respiratory Research  (2018) 19:8 Page 5 of 6
Piepoli MF, Ponikowski P, Revel MP, Rigau D, Rosenkranz S, Völler H, Luis
Zamorano J. 2015 ESC/ERS guidelines for the diagnosis and treatment of
pulmonary hypertension: the joint task force for the diagnosis and treatment
of pulmonary hypertension of the European Society of Cardiology (ESC) and
the European Respiratory Society (ERS): endorsed by: Association for European
Pediatric and Congenital Cardiology (AEPC), International Society for Heart and
Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.
2. Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, Welte T,
Hoeper MM. The prognostic impact of followup assessments in patients
with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012;39(3):
589–96. https://doi.org/10.1183/09031936.00092311.
3. Lewis GD, Bossone E, Naeije R, Grünig E, Saggar R, Lancellotti P, Ghio S, Varga J,
Rajagopalan S, Oudiz R, Rubenfire M. Pulmonary vascular hemodynamic
response to exercise in cardiopulmonary diseases. Circulation. 2013;128(13):
1470–9. https://doi.org/10.1161/CIRCULATIONAHA.112.000667.
4. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart
Fail. 2004;6(3):257–60.
5. Souza R, Jardim C, Julio Cesar Fernandes C, Silveira Lapa M, Rabelo R,
Humbert M. NT-proBNP as a tool to stratify disease severity in pulmonary
arterial hypertension. Respir Med. 2007;101(1):69–75.
6. Wasserman K, Handen J, Sue D. Principles of exercise testing and
interpretation. Philadelphia, USA: Lippincott Williams & Wilkins; 2004.
7. Borg G. Borg’s perceived exertion and pan scales. Champaign, IL: Human
Kinetics; 1998.
8. Capoulade R, Magne J, Dulgheru R, Hachicha Z, Dumesnil JG, O'Connor K,
Arsenault M, Bergeron S, Pierard LA, Lancellotti P, Pibarot P. Prognostic
value of plasma B-type natriuretic peptide levels after exercise in patients
with severe asymptomatic aortic stenosis. Heart. 2014;100(20):1606–12.
9. Kato M, Kinugawa T, Ogino K, Endo A, Osaki S, Igawa O, Hisatome I,
Shigemasa C. Augmented response in plasma brain natriuretic peptide to
dynamic exercise in patients with leftventricular dysfunction and congestive
heart failure. J Intern Med. 2000;248(4):309–15.
10. Maeder MT, Staub D, Surnier Y, Reichlin T, Noveanu M, Breidthardt T,
Potocki M, Schaub N, Conen D, Mueller C. Determinants of absolute and
relative exercise-induced changes in B-type natriuretic peptides. Int J
Cardiol. 2011;147(3):409–15. https://doi.org/10.1016/j.ijcard.2009.09.546.
11. Grachtrup S, Brügel M, Pankau H, Halank M, Wirtz H, Seyfarth HJ. Exercise
dependence of N-terminal pro-brain natriuretic peptide in patients with
precapillary pulmonary hypertension. Respiration. 2012;84(6):454–60. https://
doi.org/10.1159/000334950.
12. Völkers M, Rohde D, Zelniker T, Weiss CS, Giannitsis E, Katus HA, Meyer FJ.
High-sensitive Troponin T increase after exercise in patients with pulmonary
arterial hypertension. BMC Pulm Med. 2013;13:28. https://doi.org/10.1186/
1471-2466-13-28.
13. Arena R, Myers J, Williams MA, Gulati M, Kligfield P, Balady GJ, Collins E,
Fletcher G. Assessment of functional capacity in clinical and research
settings: a scientific statement from the American Heart Association
Committee on exercise, rehabilitation, and prevention of the council on
clinical cardiology and the council on cardiovascular nursing. Circulation.
2007;116:329–43.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kutsch et al. Respiratory Research  (2018) 19:8 Page 6 of 6
